FDA
-
-
-
-
-
-
-
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on T
-
-
-
-
-
-
-
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
-
-
-
-
-
-
-
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
-
-
-
-
-
-
-
FDA accepts Priovant's drug application for dermatomyositis treatment
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Organon (OGN) Completes Acquisition of Dermavant
-
-
-
-
-
-
-
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
-
330,635 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

